[A22-69] Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

Last updated 17.10.2022

Project no.:

Commission awarded on 12.07.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Muscles, bones and joints


Alone or in combination with methotrexate for the treatment of active enthesitis-associated arthritis in patients aged 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy

Result of dossier assessment:

Added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form